Pediatr Allergy Immunol. 2024 Feb;35(2): e14073
Eduardo Liquidano-Perez,
Gibert Maza-Ramos,
Bethy Alexandra Perez Arias,
Saul Oswaldo Lugo Reyes,
Tania Barragan Arevalo,
Sara Alejandra Solorzano-Morales,
Edna Venegas Montoya,
Aidé Tamara Staines-Boone,
Rogelio Guzmán Cotaya,
Satoshi Okada,
Capucine Picard,
Etienne Patin,
Nideshda Ramirez-Uribe,
Juan Carlos Bustamante-Ogando,
Selma Cecilia Scheffler-Mendoza,
Marco Antonio Yamazaki-Nakashimada,
Marimar Saez-de-Ocariz,
Sara Elva Espinosa Padilla,
Maria Edith Gonzalez-Serrano.
PURPOSE: We aimed to describe the clinical, immunological, and genetic features of patients with DOCK8 deficiency (DOCK8-Def) in a tertiary care center for children.METHODS: Retrospective chart review of patients' clinical, immunological, and genetic characteristics with DOCK8-Def. Genetic analysis was performed with targeted- or whole-exome sequencing; we also assessed DOCK8 protein expression and a lymphoproliferation assay and analyzed survival by the Kaplan-Meier method.
RESULTS: We described 11 patients from 8 unrelated kindreds. The median age at symptoms' onset was 10 months (range 1-54 months). The median follow-up time was 53.4 months (4.8-118.8). All patients presented eczema and recurrent sinopulmonary and cutaneous infections. Besides those symptoms, the most frequent manifestations were bronchiectases (8/11), food allergies (6/11), and severe infections (6/11). Infrequent characteristics were detection of CMV in bronchial lavage, C. parvum-driven sclerosing cholangitis, Takayasu vasculitis, neurological syndromes, pulmonary tuberculosis, and lymphomatoid granulomatosis.
CONCLUSION: DOCK8-Def has a broad spectrum of manifestations, including allergy, autoimmunity, inflammation, infection, and cancer. The hallmark of this inborn error of immunity is IEI-associated eczema with eosinophilia and increased IgE. Here, we report six new mutations causing human DOCK8 deficiency and symptoms previously unrecognized to occur in DOCK8-Def. Therefore, an early diagnosis of DOCK8-Def is essential to facilitate an adequate treatment such as HSCT.
Keywords: DOCK8 protein; eczema; hyper-IgE syndrome; immunodeficiency-associated eczema; immunologic deficiency syndromes